Stocks and Investing Stocks and Investing
Mon, September 23, 2024
Fri, September 20, 2024

Kristen Kluska Reiterated (SRPT) at Hold and Held Target at $152 on, Sep 20th, 2024


Published on 2024-10-28 14:23:48 - WOPRAI, Kristen Kluska
  Print publication without navigation


Kristen Kluska of Cantor Fitzgerald, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Hold and Held Target at $152 on, Sep 20th, 2024.

Kristen has made no other calls on SRPT in the last 4 months.



There are 11 other peers that have a rating on SRPT. Out of the 11 peers that are also analyzing SRPT, 1 agrees with Kristen's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Hoang of "Citigroup" Maintained at Hold with Decreased Target to $160 on, Thursday, August 8th, 2024


These are the ratings of the 10 analyists that currently disagree with Kristen


  • Brian Abrahams of "RBC Capital" Reiterated at Buy and Held Target at $181 on, Thursday, September 19th, 2024
  • Biren Amin of "Piper Sandler" Maintained at Buy with Decreased Target to $200 on, Thursday, August 8th, 2024
  • Gavin Clark-Gartner of "Evercore ISI Group" Upgraded from Hold to Buy and Decreased Target to $179 on, Thursday, August 8th, 2024
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $203 on, Thursday, August 8th, 2024
  • Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $235 on, Thursday, June 27th, 2024
  • Kostas Biliouris of "BMO Capital" Maintained at Buy with Increased Target to $200 on, Monday, June 24th, 2024
  • Mani Foroohar of "Leerink Partners" Maintained at Buy with Increased Target to $230 on, Monday, June 24th, 2024
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $200 on, Monday, June 24th, 2024
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $213 on, Friday, June 21st, 2024
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $200 on, Friday, June 21st, 2024
Contributing Sources